Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tenon Medical (TNON) Income towards Parent Company (2021 - 2025)

Historic Income towards Parent Company for Tenon Medical (TNON) over the last 5 years, with Q3 2025 value amounting to -$3.4 million.

  • Tenon Medical's Income towards Parent Company fell 550.54% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.1 million, marking a year-over-year increase of 497.64%. This contributed to the annual value of -$13.8 million for FY2024, which is 1236.98% up from last year.
  • According to the latest figures from Q3 2025, Tenon Medical's Income towards Parent Company is -$3.4 million, which was down 550.54% from -$2.9 million recorded in Q2 2025.
  • Over the past 5 years, Tenon Medical's Income towards Parent Company peaked at -$200000.0 during Q1 2021, and registered a low of -$7.9 million during Q4 2022.
  • In the last 5 years, Tenon Medical's Income towards Parent Company had a median value of -$3.3 million in 2022 and averaged -$3.5 million.
  • As far as peak fluctuations go, Tenon Medical's Income towards Parent Company tumbled by 107650.0% in 2022, and later surged by 6012.63% in 2023.
  • Tenon Medical's Income towards Parent Company (Quarter) stood at -$2.8 million in 2021, then plummeted by 178.58% to -$7.9 million in 2022, then skyrocketed by 60.13% to -$3.2 million in 2023, then fell by 0.47% to -$3.2 million in 2024, then fell by 6.9% to -$3.4 million in 2025.
  • Its Income towards Parent Company stands at -$3.4 million for Q3 2025, versus -$2.9 million for Q2 2025 and -$3.7 million for Q1 2025.